molecules of the month


allosteric mutant IDH1/2 dual inhibitor

oral, brain penetrant, completed Ph. I in HV

from SBDD of prior mIDH inhibitor

ACS Med. Chem. Lett., 2020, 11, 101-107

Agios Pharmaceuticals, Cambridge, MA

1 min read

AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: